Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats

European Journal of Pharmaceutical Sciences

Volumn 37, Issue 3-4, 2009, Pages 413-417

  Qiang, Fu ^a   Lee, Beom Jin ^b   Lee, Wonjae ^a   Han, Hyo Kyung ^a  

^a Chosun University   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

Drug interaction; Fexofenadine; Fluvastatin; Organic anion transporting polypeptides; Rat

Indexed keywords

FEXOFENADINE; FLUINDOSTATIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER POLYPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL TRANSPORT; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG UPTAKE; INTESTINE; INTESTINE ABSORPTION; LIVER; MALE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE;

ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; FATTY ACIDS, MONOUNSATURATED; HISTAMINE H1 ANTAGONISTS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INTESTINAL ABSORPTION; MALE; ORGANIC ANION TRANSPORTERS; RATS; RATS, SPRAGUE-DAWLEY; TERFENADINE;

EID: 66049098891     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.03.012     Document Type: Article

References (29)

1. Hagenbuch B., and Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38 (2008) 778-801
2. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8 (2007) 787-802
3. Mikkaichi T., Suzuki T., Tanemoto M., Ito S., and Abe T. The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet. 19 (2004) 171-179
4. Leucuta S.E., and Vlase L. Pharmacokinetics and metabolic drug interactions. Curr. Clin. Pharmacol. 1 (2006) 5-20
5. Pal D., and Mitra A.K. MDR-and CYP3A4-mediated drug-drug interactions. J. Neuroimmun. Pharmacol. 1 (2006) 323-339
6. Simpson K., and Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59 (2000) 301-321
7. Devillier P., Roche N., and Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin. Pharmacokinet. 47 (2008) 217-230
8. Molimard M., Diquet B., and Benedetti M.S. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam. Clin. Pharmacol. 18 (2004) 399-411
9. Tahara H., Kusuhara H., Fuse E., and Sugiyama Y. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab. Dispos. 33 (2005) 963-968
10. Milne R.W., Larsen L.A., Jørgensen K.L., Bastlund J., Stretch G.R., and Evans A.M. Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein. Pharm. Res. 17 (2000) 1511-1515
11. Shimizu M., Fuse K., Okudaira K., Nishigaki R., Maeda K., Kusuhara H., and Sugiyama Y. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 33 (2005) 1477-1481
12. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., and Kim R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27 (1999) 866-871
13. Dresser G.K., Kim R.B., and Bailey D.G. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. 77 (2005) 170-177
14. Dresser G.K., Bailey D.G., Leake B.F., Schwarz U.I., Dawson P.A., Freeman D.J., and Kim R.B. Fruit juices inhibit organic anion transporting polypeptidemediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71 (2002) 11-20
15. Kamath A.V., Yao M., Zhang Y., and Chong S. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J. Pharm. Sci. 94 (2005) 233-239
16. Kathawala F.G. HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med. Res. Rev. 11 (1991) 121-146
17. Davignon J., Montigny M., and Dufcur R. HMG-COA reductase inhibitors: a look back and a look ahead. Can. J. Cardiol. 8 (1992) 843-864
18. Scripture C.D., and Pieper J.A. Clinical pharmacokinetics of fluvastatin. Clin. Pharmacokinet. 40 (2001) 263-281
19. Dain J.G., Fu E., Gorski J., Nicoletti J., and Scallen T.J. Biotransformation of fluvastatin sodium in humans. Drug Metab. Dispos. 21 (1993) 567-572
20. Nozawa T., Imai K., Nezu J., Tsuji A., and Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in humans. J. Pharmacol. Exp. Ther. 308 (2004) 438-445
21. Noé J., Portmann R., Brun M.E., and Funk C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos. 35 (2007) 1308-1314
22. Rocha A., Coelho E.B., and Lanchote V.L. Stereospecific disposition of fluvastatin in streptozotocin-induced diabetic rats. Can. J. Physiol. Pharmacol. 80 (2002) 1071-1075
23. Kikuchi A., Nozawa T., Wakasawa T., Maeda T., and Tamai I. Transporter-mediated intestinal absorption of fexofenadine in rats. Drug Metab. Pharmacokinet. 21 (2006) 308-314
24. Fischer V., Johanson L., Heitz F., Tullman R., Graham E., Baldeck J.P., and Robinson W.T. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos. 27 (1999) 410-416
25. Bogman K., Peyer A.K., Török M., Küsters E., and Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. 132 (2001) 1183-1192
26. Appel S., Rüfenacht T., Kalafsky G., Tetzloff W., Kallay Z., Hitzenberger G., and Kutz K. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am. J. Cardiol. 76 (1995) 29A-32A
27. Kivistö K.T., Kantola T., and Neuvonen P.J. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br. J. Clin. Pharmacol. 46 (1998) 49-53
28. Peters T.K., Jewitt-Harris J., Mehra M., and Muratti E.N. Safety and tolerability of fluvastatin with concomitant use of antihypertensive agents: an analysis of a clinical trial database. Am. J. Hypertens. 6 (1993) 346S-352S
29. Neuvonen P.J., Backman J.T., and Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin. Pharmacokinet. 47 (2008) 463-474